Home › Trials › NCT06414954

Evaluating NMD670 for treating Myasthenia Gravis in adults

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 Over 21 Days in Adult Patients With AChR/MuSK-Ab+ Myasthenia Gravis

Phase 2 Interventional NMD Pharma A/S · NCT06414954

This study is testing if a new medication called NMD670 can help adults with Myasthenia Gravis feel better by comparing different doses to a placebo.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment84 (estimated)
Ages18 Years and up
SexAll
SponsorNMD Pharma A/S Industry-sponsored
Locations40 sites (Carlsbad, California and 39 other locations)
Trial IDNCT06414954 on ClinicalTrials.gov

What this trial studies

This Phase 2 proof-of-concept study investigates the safety and efficacy of three different dose levels of NMD670 compared to a placebo in adult patients diagnosed with Myasthenia Gravis who have antibodies against AChR or MuSK. Participants will receive the treatment twice daily for a duration of 21 days. The study aims to determine the optimal dose that balances safety and effectiveness in managing symptoms of this condition.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with a confirmed diagnosis of Myasthenia Gravis and positive AChR or MuSK antibody tests.

Not a fit: Patients with other significant medical or psychological conditions that may interfere with study participation or outcomes may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve the management of Myasthenia Gravis symptoms in affected patients.

How similar studies have performed: While this approach is being tested in this specific context, similar studies have shown promise in evaluating new treatments for Myasthenia Gravis.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Participant must be a male or female being 18 or more, at the time of signing the informed consent
* Diagnosis of MG, MGFA class II, III or IV
* Documented positive AChR or MuSK antibody test.
* Participant must be able to swallow tablets
* Body mass index between 18 and 35 kg/m2, inclusive, at screening, and with a minimum weight of 40 kg
* Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
* Participant is capable of and has given signed informed consent

Exclusion Criteria:

* Known medical or psychological condition(s) or risk factor that, in the opinion of the Investigator, might interfere with the patient's full participation in the study, pose any additional risk for the patient, or confound the assessment of the patient or outcome of the study
* Participants with other significant clinical and/or laboratory safety findings that may interfere with the conduction or interpretation of the study
* Participants that received treatment with an investigational medical product within 30 days or 5 half-lives of the medication, whichever is longer prior to Day 1
* Participants with history of poor compliance with relevant MG therapy
* Female patients who plan to become pregnant during the study or are currently pregnant or breastfeeding

Where this trial is running

Carlsbad, California and 39 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Myasthenia GravisMyasthenia Gravis, MuSK
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.